Sign in

TRIB on Nasdaq

TRINITY BIOTECH PLC

In vitro and in vivo diagnostic substances company, listed on Nasdaq (TRIB)1

In its 2026 annual report (Form 20-F) the company says: “We are a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Through our subsidiaries, we develop, acquire, manufacture and market medical diagnostic products for the clinical laboratory and point‑of‑care segments of the diagnostic market. Our products are used to detect autoimmune, infectious and sexually transmitted diseases, disorders of the liver and intestine, and to monitor markers for diabetes.”3

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Intellia Therapeutics, Alpha Teknova, Inc. or IMMUCELL CORP /DE/, or pick any stock.

  • TickerTRIB on Nasdaq1
  • IndustryIn Vitro & In Vivo Diagnostic Substances1
  • HeadquartersL21
  • Incorporated inIreland2
  • Business addressIda Business Park, Bray, Wicklow2
  • Filer categoryNon-accelerated filer2

See how the biggest companies compare on our leaderboards

We were incorporated in Ireland in 1992 as a private limited company and re-registered as a public limited company (“plc”) in July of that year. In October 1992 we completed an initial public offering of our securities in the United States and our ADS have traded on the Nasdaq Global Market since that time under the symbol “TRIB”.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

34.8%Gross margin4
-34.4%Operating margin4
-50.7%Net margin4
8.3%Revenue growth, 20244
-$4.6MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Clinical Laboratory brought in 72% of the revenue TRINITY BIOTECH PLC broke down this way in fiscal 2025.

  1. Clinical Laboratory$31.7M572%down 20% from 2024
  2. Point-of-Care$8.1M519%down 54% from 2024
  3. Laboratory Services$4.0M59%down 16% from 2024
Products and services by year
Products and services202320242025
Clinical Laboratory$42.3M$39.4M$31.7M
Point-of-Care$9.1M$17.4M$8.1M
Laboratory Services$5.5M$4.8M$4.0M

Regions

United States brought in 78% of the revenue TRINITY BIOTECH PLC broke down this way in fiscal 2025.

  1. United States$52.0M578%down 16% from 2024
  2. Ireland$15.0M522%down 27% from 2024
Regions by year
Regions202320242025
United States$66.9M$61.6M$52.0M
Ireland$12.7M$20.5M$15.0M

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue48¢$40.1M
  • Research and development5¢$4.5M
  • Selling, general and admin34¢$28.8M
  • Interest11¢$9.6M
  • Income tax1¢$486.0K

Out of $61.6M in revenue.4 The company lost money this year.

Financial statements

Revenue67894$61.6M in 2024−37% since 2018
0$50.0M$100.0M$150.0M2018: $97.0M$97.0M20182019: $90.4M$90.4M2019−7%2020: $102.0M$102.0M2020+13%2021: $81.1M$81.1M2021−20%2022: $62.5M$62.5M2022−23%2023: $56.8M$56.8M2023−9%2024: $61.6M$61.6M2024+8%
Gross profit67894$21.4M in 2024−48% since 2018
0$20.0M$40.0M$60.0M2018: $41.4M$41.4M20182019: $38.1M$38.1M2019−8%2020: $48.6M$48.6M2020+27%2021: $33.5M$33.5M2021−31%2022: $17.3M$17.3M2022−48%2023: $19.4M$19.4M2023+13%2024: $21.4M$21.4M2024+10%
Operating income67894-$21.2M in 2024+5% since 2018
-$30.0M-$20.0M-$10.0M0$10.0M2018: -$20.2M-$20.2M20182019: -$24.1M-$24.1M2019+19%2020: $82.0K$82.0K20202021: $3.9M$3.9M2021+4702%2022: -$19.3M-$19.3M20222023: -$27.0M-$27.0M2023+40%2024: -$21.2M-$21.2M2024−22%
Net income67894-$31.2M in 2024+38% since 2018
-$60.0M-$40.0M-$20.0M02018: -$22.7M-$22.7M20182019: -$29.0M-$29.0M2019+28%2020: -$6.0M-$6.0M2020−79%2021: -$1.9M-$1.9M2021−69%2022: -$43.6M-$43.6M2022+2256%2023: -$36.9M-$36.9M2023−15%2024: -$31.2M-$31.2M2024−15%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenues$43.8M$61.6M$56.8M
Cost of sales-$26.9M-$40.1M-$37.4M
Gross profit$16.9M$21.4M$19.4M
Other operating income/(expense)$1.9M-$1.8M$141.0K
Research and development expenses-$3.6M-$4.5M-$4.4M
Selling, general and administrative expenses-$24.7M-$28.8M-$31.2M
Selling, general and administrative expenses Transformation costs-$4.3M-$4.2M$0
Once off items$186.0K-$1.9M$0
Impairment charges-$2.2M-$1.4M-$11.1M
Operating loss-$15.8M-$21.2M-$27.0M
Financial income$0$0$1.2M
Financial expenses-$21.4M-$9.6M-$11.1M
Net financing expense-$21.4M-$9.6M-$9.9M
Loss before tax-$37.2M-$30.7M-$36.9M
Total income tax (expense)/credit-$199.0K-$486.0K$59.0K
Loss for the year on continuing operations-$37.4M-$31.2M-$36.9M
(Loss)/profit for the year on discontinued operations$0-$573.0K$12.8M
Loss for the year (all attributable to owners of the parent)-$37.4M-$31.8M-$24.0M

Compare TRINITY BIOTECH PLC with another company

Corporate structure

TRINITY BIOTECH PLC sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of TRINITY BIOTECH PLC

  • TRINITY BIOTECH PLC L2

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What TRINITY BIOTECH PLC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$4.6M4 Dec 31, 2024$1.9M4 Dec 31, 2023+144.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.2M4 Dec 31, 2024$3.7M4 Dec 31, 2023+40.0%
Long-term investments$2.5M4 Dec 31, 2024$04 Dec 31, 2023

Inventory

ItemLatestA year beforeChange
Inventory, total$19.4M4 Dec 31, 2024$19.9M4 Dec 31, 2023−2.8%
Raw materials$10.0M4 Dec 31, 2024$10.1M4 Dec 31, 2023−0.2%

Leadership

Who has led TRINITY BIOTECH PLC, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (4)

Filings

235 filings to the SEC since October 2021: 7 annual reports, 6 insider forms, 22 large holders, 200 other. The latest 20:

  1. Oct 5, 20266-K EDGAR
  2. Sep 9, 20266-K EDGAR
  3. Sep 8, 20266-K EDGAR
  4. Sep 1, 2026EFFECT EDGAR
  5. Aug 28, 20266-K EDGAR
  6. Aug 28, 2026POS AM EDGAR
  7. Aug 27, 2026AW EDGAR
  8. Aug 21, 2026F-1/A EDGAR
  9. Aug 17, 20266-K EDGAR
  10. Aug 14, 20266-K EDGAR
  11. Jul 22, 20266-K EDGAR
  12. Jul 22, 20266-K EDGAR
  13. Jul 2, 20266-K EDGAR
  14. Jun 30, 20266-K EDGAR
  15. Jun 29, 20266-K EDGAR
  16. Jun 23, 2026424B3 EDGAR
  17. Jun 23, 20266-K EDGAR
  18. Jun 18, 2026424B3 EDGAR
  19. Jun 18, 20266-K EDGAR
  20. Jun 15, 2026424B3 EDGAR

The 235 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How TRINITY BIOTECH PLC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTRINITY BIOTECH PLC1
  • CIK0000888721
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company3
  • Incorporated inIreland3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressIda Business Park, Bray, Wicklow, Ireland1
  • Phone011353129551111
  • Shares outstanding374,206,640 shares as of Dec 31, 20253
  • AuditorGRANT THORNTON, Dublin, Ireland PCAOB ID 1402; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceSep 9, 19961
  • Filings500 in all: 6-K (228), SC 13G/A (47), 20-F (28), CORRESP (26), UPLOAD (25), SC 13G (20), 424B3 (19), F-3 (16)1
    All 31 form types

    EFFECT (14), SCHEDULE 13D/A (10), 424B5 (9), 20-F/A (7), F-3/A (6), 3 (5), S-8 (5), SC 13D/A (5), NT 20-F (4), SC 13D (4), POS AM (3), S-8 POS (3), AW (2), F-1 (2), F-1/A (2), REGDEX (2), RW (2), 3/A (1), 424B1 (1), F-3MEF (1), S-3 (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (20-F) Apr 30, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares (each representing 20‘A’ Ordinary Shares, par value US$0.0001)TRIBNASDAQ

From the cover page of the 20-F filed Apr 30, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22